11/4/2019 Investor Update * BIEL is consulting
Post# of 7807
(Total Views: 402)
Posted On: 11/04/2019 11:28:11 AM
11/4/2019 Investor Update
* BIEL is consulting with lawyers to confirm proper process for BOD and CEO appointments.
* The Allay Clinical Study conducted by Birmingham Women’s Hospital, a 170 year old UK NHS Trust facility, has been completed. They are now in the data analysis phase.
* A call was held with the FDA regarding the Musculoskeletal Pain 510(k). The FDA said staff shortages had caused unexpected delays. BIEL submitted additional information on 11/1. The expectation is for the Substantive Review to begin next week.
* A 3 Year ISO 13485:2016 certificate should be issued within the next 2 weeks.
* On 10/31 BIEL was advised by their Notified Body, NEMKO/Presafe, that the Review of their CE Re-Certification will begin the week of 11/7. This is the final step before CE Certification.
* BIEL is waiting on Audit dates for its MDSAP certification which will satisfy the new requirements for Brazil, Canada, USA, Japan & Australia.
* BIEL had a meeting with a company who they were formerly engaged with regarding a Plantar Fasciitis Product Partnership. The meeting went well and further meetings are scheduled. BIEL has phone meetings scheduled with two "large players" in the "commercial space".
* A 15,000-unit order for shipment to MundiPharma Singapore is being prepared.
* BIEL is finalizing discussions with MundiPharma for adding up to 30 countries in the Middle East and North Africa region.
* One of BIEL's channel partners (a channel partner is a third-party organization or individual that markets and sells products, services or technologies for a manufacturer or service provider via a partnering relationship AKA Co-Branding), has a Deal with an American Multinational Health Care Services company to place ActiPatch in 1000 Independently Owned Stores under an initiative for Alternative Pain Therapies, late Q1 2020 Launch.
* BIEL has signed agreements with two Veteran Owned companies who currently do business with the VA to promote VA use of BIEL products.
* BIEL is consulting with lawyers to confirm proper process for BOD and CEO appointments.
* The Allay Clinical Study conducted by Birmingham Women’s Hospital, a 170 year old UK NHS Trust facility, has been completed. They are now in the data analysis phase.
* A call was held with the FDA regarding the Musculoskeletal Pain 510(k). The FDA said staff shortages had caused unexpected delays. BIEL submitted additional information on 11/1. The expectation is for the Substantive Review to begin next week.
* A 3 Year ISO 13485:2016 certificate should be issued within the next 2 weeks.
* On 10/31 BIEL was advised by their Notified Body, NEMKO/Presafe, that the Review of their CE Re-Certification will begin the week of 11/7. This is the final step before CE Certification.
* BIEL is waiting on Audit dates for its MDSAP certification which will satisfy the new requirements for Brazil, Canada, USA, Japan & Australia.
* BIEL had a meeting with a company who they were formerly engaged with regarding a Plantar Fasciitis Product Partnership. The meeting went well and further meetings are scheduled. BIEL has phone meetings scheduled with two "large players" in the "commercial space".
* A 15,000-unit order for shipment to MundiPharma Singapore is being prepared.
* BIEL is finalizing discussions with MundiPharma for adding up to 30 countries in the Middle East and North Africa region.
* One of BIEL's channel partners (a channel partner is a third-party organization or individual that markets and sells products, services or technologies for a manufacturer or service provider via a partnering relationship AKA Co-Branding), has a Deal with an American Multinational Health Care Services company to place ActiPatch in 1000 Independently Owned Stores under an initiative for Alternative Pain Therapies, late Q1 2020 Launch.
* BIEL has signed agreements with two Veteran Owned companies who currently do business with the VA to promote VA use of BIEL products.
(0)
(0)BioElectronics Corporation (BIEL) Stock Research Links
Scroll down for more posts ▼